evitria
evitria is a Zurich-based contract research organization providing custom recombinant antibody and protein production services in CHO cells for biotech and pharmaceutical companies globally, with a 4-week standard turnaround and licensed technology platforms for bispecific, afucosylated, and Fc-silenced formats.
- Company typePrivate
- Founded2010
- HeadquartersZürich, Switzerland
- Headcount11–50
- GTM typeB2B
- OfferingServices
What evitria does
evitria AG is a privately held contract research organization founded in 2010 and headquartered in Zurich-Fahrweid, Switzerland. The company provides custom recombinant antibody and protein production services using a Chinese Hamster Ovary (CHO) cell-based transient expression platform, serving biotech, biopharmaceutical, academic and government research customers across North America, Europe and Asia-Pacific. Its service portfolio covers six core offerings — standard recombinant IgG production, bispecific antibodies, afucosylated (ADCC-enhanced) antibodies, Fc-silenced antibodies, high-throughput parallel expression, and non-antibody recombinant proteins — delivered with a standard 4-week turnaround, >95% purity on bispecific formats, and endotoxin levels below 1 EU/mg.
The technical differentiation rests on a stack of licensed proprietary platforms: GlymaxX® from ProBioGen for glycoengineering and fucose modulation, Opti-mAb® from AAX Biotech for scFv stabilization in bispecific formats, STR (True Fc Silencing) from mAbsolve for Fc-null antibodies, and bYlok® from Lonza for correct heavy- and light-chain pairing in IgG-like bispecifics. Since founding, evitria has executed over 140,000 transfections and delivered more than 25,000 antibodies, reflecting 15 years of accumulated CHO process know-how.
Commercially, evitria operates a B2B professional services model with quote-based, pay-as-you-go project pricing determined by antibody format, scale, timeline and quality requirements. Distribution is direct via the company website, email contact, and regional business development managers (e.g., Manchester/Great Britain coverage by Brad Gartland), supported by industry conference participation and an educational Antibody Journal content marketing program. Revenue is generated entirely from custom antibody and protein production service fees; no platform licensing, milestone, or royalty streams are disclosed.
evitria firmographics
Firmographics- Name
- evitria
- Legal name
- evitria AG
- Website
- https://evitria.com
- Company type
- Private
- Founded year
- 2010
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- evitria is a Zurich-based contract research organization providing custom recombinant antibody and protein production services in CHO cells for biotech and pharmaceutical companies globally, with a 4-week standard turnaround and licensed technology platforms for bispecific, afucosylated, and Fc-silenced formats.
- Ownership category
- akta.pro rank
evitria industry classification
Industry- Product category
- Contract Antibody Production Services
- akta.pro primary industry
- Exosome & Extracellular Vesicle (EV) Therapeutics (HLAMANAE)
- akta.pro secondary industry
- Bispecific & Multispecific Antibodies (HLAAAAAF)
Keywords
Where evitria is headquartered
LocationHeadquarters
- HQ city
- Zürich
- HQ country
- Switzerland
- HQ region
- Europe
Offices1 record
Markets served
evitria business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Custom Antibody Expression Services: evitria provides custom recombinant antibody production services in CHO cells, generating revenue through project-based fees. Services include recombinant IgG production, bispecific antibodies, afucosylated antibodies, Fc-silenced antibodies, high-throughput production, and other recombinant proteins. Pricing is quote-based and depends on antibody format, production scale, timeline, and quality requirements.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Quote-based pricing tailored to project requirements |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels6 records
evitria product offering
Product offeringCore offering
evitria is a CRO providing custom recombinant antibody production services using an optimized CHO (Chinese Hamster Ovary) cell-based transient expression platform. Services span standard IgG production, bispecific and multispecific antibody formats, afucosylated (ADCC-enhanced) antibodies, Fc-silenced antibodies, high-throughput parallel expression, and other recombinant proteins, with a 4-week standard turnaround from sequence to purified protein.
Product overview
evitria is a contract research organization (CRO) providing custom antibody production services using an optimized CHO cell expression platform. The company's portfolio includes six distinct service offerings: Recombinant Antibody Expression Service (standard IgG production), Bispecific Antibody Production Service (dual-targeting formats), Afucosylated Antibody Expression Service (ADCC-enhanced via GlymaxX®), Fc-Silenced Antibody Production Service (reduced effector function via STR technology), High-Throughput Antibody Production Service (parallel expression of hundreds of constructs), and Recombinant Protein Expression Service (non-antibody proteins). These services are powered by three licensed technology platforms: GlymaxX® for glycoengineering, Opti-mAb® for scFv stabilization, and STR for true Fc silencing. All production uses mammalian (CHO) cell-based transient expression with a 4-week standard turnaround.
Differentiator
Problem solved
Functional benefit
Products and services
- Recombinant Antibody Expression Service Custom production of recombinant monoclonal antibodies in CHO cells, delivering purified proteins from antibody sequences in as little as 4 weeks, with low endotoxin levels (<1 EU/mg). Standard IgG production for biotech and pharma therapeutic programs.
- Bispecific Antibody Production Service Production of bispecific antibodies capable of simultaneously binding to two different antigens or epitopes. Uses bYlok® technology from Lonza to address heavy-light chain mispairing challenges, with >95% purity achievable.
- Afucosylated Antibody Expression Service Production of afucosylated antibodies lacking fucose residues in the Fc region, resulting in enhanced antibody-dependent cellular cytotoxicity (ADCC) for increased therapeutic potency in oncology applications. Uses GlymaxX® glycoengineering technology.
- Fc-Silenced Antibody Production Service Production of antibodies with reduced or eliminated Fc effector functions using STR (True Fc Silencing) technology from mAbsolve, ideal for neutralizing interactions without triggering immune responses.
- High-Throughput Antibody Production Service Parallel expression of up to several hundred antibody constructs per project, delivering purified, assay-ready material in as little as 4 weeks with >95% purity. Designed for AI-driven antibody discovery and optimization pipelines.
- Recombinant Protein Expression Service Production of non-antibody soluble proteins including antigens, extracellular domains, cytokines, viral proteins, and alternative scaffolds using the CHO cell expression platform.
Quantifiable outcome
- 140,000+ transfections and 25,000+ antibodies delivered since 2010
- +5 more outcomes
Companies that use evitria
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles2 records
evitria technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
evitria partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- AAX BiotechcorePartnership to enable use of Opti-mAb® technology in early antibody development workflows. AAX Biotech develops proprietary technologies including Opti-mAb® supporting antibody-based therapies. The partnership expands access to scFv stabilization technology for bispecific antibody development.
- LonzacoreNon-exclusive license agreement for bYlok® technology enabling simple and reliable development of IgG-like bispecific antibodies. Addresses the challenge of correct heavy chain and light chain pairing in bispecific antibody generation for discovery-stage transient expression research.
- ProBioGencoreExclusive licensing partnership for GlymaxX® technology enabling modulation of fucosylation in CHO cells. The technology uses a deflecting enzyme to deplete fucose monosaccharides from glycosylation pathways, allowing fine-tuning from complete lack to fully fucosylated variants. Critical for producing ADCC-enhanced afucosylated antibodies.
- Atlas AntibodiesminorListed as a partnership on evitria's partnerships page. Nature of partnership not detailed in available sources.
- Integral MolecularminorListed as a partnership on evitria's HTML sitemap. Nature of partnership not detailed in available sources.
Scale indicators10 records
Recent moves6 records
Expansion highlights6 records
evitria competitors and assessment
Company assessmentBroad incumbents
- Lonza: Global CDMO offering end-to-end biologics services including mammalian cell expression, stable cell line development, and GMP manufacturing. Direct comparability on transient and stable CHO expression; Lonza also licenses bYlok® to evitria, making it both a partner and broader incumbent.
- Charles River Laboratories: Global CRO/CDMO with extensive biologics and antibody discovery services. Comparable through its Antibody Discovery & Optimization offerings; Brad Gartland (evitria's BDM) previously held senior commercial roles at Charles River, highlighting operational overlap.
- WuXi Biologics: Global biologics CDMO offering discovery through GMP manufacturing with extensive mammalian cell expression capacity. Comparable on CHO-based transient and stable expression but at much larger scale across the value chain.
- Catalent: Global CDMO with biologics capabilities including mammalian cell line development and biopharmaceutical manufacturing. Comparable in the broader biologics services space, particularly for customers needing integrated discovery-to-GMP workflows.
Direct peers
- GenScript ProBio: Provides custom antibody and protein production services using mammalian (HEK/CHO) expression, including recombinant antibody expression, bispecific antibody production, and high-throughput formats. Directly competes with evitria on CHO-based transient expression for biotech and pharma customers.
- ProBioGen: Berlin-based CDMO specializing in mammalian cell engineering, cell line development, and viral vectors. Also licenses its GlymaxX® technology to evitria, making it both a core technology partner and a peer offering CHO-based expression services with proprietary glycoengineering capabilities.
- Absolute Antibody: Recombinant antibody production and engineering services including antibody reformatting, Fc-engineering, and custom expression. Comparable to evitria on recombinant mAb and Fc-engineered antibody services for therapeutic and research customers.
- Sino Biological: Recombinant antibody and protein production CRO with HEK293 and CHO cell expression, including bispecific and Fc-engineered formats. Directly comparable service portfolio serving global biotech and pharma with custom antibody expression.
- Creative Biolabs: Custom antibody services including recombinant antibody production, antibody engineering, bispecific antibody development, and Fc-silencing. Direct competitor to evitria across the full antibody expression service stack.
Emerging players
- mAbsolve: Developer of the STR (True Fc Silencing) technology that evitria licenses. A focused emerging player in Fc-silenced antibody tools, providing complementary technology and direct partnership/peer dynamics with evitria.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
evitria social profiles
Digital presenceevitria financial estimates
Financial estimateRevenue estimate
Valuation estimate
evitria leadership team
Management profileNumber of profiles
Profiles3 records
evitria funding detail
Funding detailFunding overview
Funding rounds1 record
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
evitria M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about evitria
What does evitria do?
evitria is a CRO providing custom recombinant antibody production services using an optimized CHO (Chinese Hamster Ovary) cell-based transient expression platform. Services span standard IgG production, bispecific and multispecific antibody formats, afucosylated (ADCC-enhanced) antibodies, Fc-silenced antibodies, high-throughput parallel expression, and other recombinant proteins, with a 4-week standard turnaround from sequence to purified protein.
Is evitria a public or private company?
evitria is a private company. It is classified as unknown and is currently operating.
When was evitria founded?
evitria was founded in 2010. It employs 11 to 50 people.
Where is evitria based?
evitria is headquartered in Zürich, Switzerland, in the Europe region.
How does evitria make money?
One revenue line is on record: custom Antibody Expression Services.
Who are evitria's main competitors?
Broad incumbents on record are Lonza, Charles River Laboratories, WuXi Biologics and Catalent. Direct peers are GenScript ProBio, ProBioGen, Absolute Antibody, Sino Biological and Creative Biolabs. mAbsolve is listed as an emerging player.
Does evitria have an API?
No public API is recorded for evitria.
What industry is evitria in?
evitria's product category is Contract Antibody Production Services. Its primary akta.pro industry code is HLAMANAE, Exosome & Extracellular Vesicle (EV) Therapeutics, with a secondary code of HLAAAAAF, Bispecific & Multispecific Antibodies.